| Combination of | |
|---|---|
| Artesunate | Antimalarial |
| Amodiaquine | Antimalarial |
| Clinical data | |
| Trade names | Camoquin, others [1] |
| Other names | ASAQ |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
 
(what is this?)
(verify) | |
Artesunate/amodiaquine, sold under the trade name Camoquin among others, is a medication used for the treatment of malaria. [3] [4] It is a fixed-dose combination of artesunate and amodiaquine. [3] Specifically it recommended for acute uncomplicated Plasmodium falciparum malaria. [5] It is taken by mouth. [4]
Common side effects include loss of appetite, nausea, abdominal pain, sleepiness, trouble sleeping, and cough. [6] Safety in pregnancy is not clear; however, the medication may be used if others are not possible. [6] It is believed to be safe for use during breastfeeding. [6] Artesunate and amodiaquine are both antimalarial medication; however, work by different mechanisms. [6]
Artesunate/amodiaquine was commercially launched in 2007. [7] It is on the World Health Organization's List of Essential Medicines. [3] Artesunate/amodiaquine is available as a generic medication. [7] As of 2014 it is not commercially available in the United States or United Kingdom. [1] [8]
Medical uses
Early clinical trials showed that a once-a-day dosage was effective. [9] It was subsequently clinically shown to be equally effective as artemether/lumefantrine, [10] although it is likely to be more effective in the field due to its simpler once-a-day dosage compared to artemether/lumefantrine twice-per-day dosage.
Society and culture
Artesunate/amodiaquine was commercially launched in 2007 as an affordable treatment for malaria, devised by DNDi in partnership with Sanofi-Aventis. [7] ASAQ was handed over to the MMV Access and Product Management Team in May 2015. [11]
References
- ^ a b Ainsworth SB (2014). "Amodiaquine with artesunate". Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life. John Wiley & Sons. p. 75. ISBN 9781118819517. Archived from the original on 2016-12-20.
- ^ https://go.drugbank.com/drugs/DB09274
- ^ a b c World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ a b Oyakhirome S, Pötschke M, Schwarz NG, Dörnemann J, Laengin M, Salazar CO, et al. (March 2007). "Artesunate--amodiaquine combination therapy for falciparum malaria in young Gabonese children". Malaria Journal. 6: 29. doi: 10.1186/1475-2875-6-29. PMC 1831475. PMID 17352806.
- ^ World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 187. hdl: 10665/44053. ISBN 9789241547659.
- ^ a b c d "Artesunate Amodiaquine Winthrop" (PDF). WIPO. August 2010. Archived (PDF) from the original on 24 October 2016. Retrieved 12 December 2016.
- ^ a b c "New, Once-a-Day Fixed-Dose Combination Against Malaria Now Available – DNDi". www.dndi.org. 1 March 2007. Archived from the original on 20 December 2016. Retrieved 12 December 2016.
- ^ Rosenthal PJ, Kamya M (2015). "Malaria". In Goldman L, Schafer AI (eds.). Goldman-Cecil Medicine. Elsevier Health Sciences. p. 2112. ISBN 9780323322850. Archived from the original on 2016-12-20.
- ^ Ndiaye JL, Randrianarivelojosia M, Sagara I, Brasseur P, Ndiaye I, Faye B, et al. (June 2009). "Randomized, multicentre assessment of the efficacy and safety of ASAQ--a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria". Malaria Journal. 8: 125. doi: 10.1186/1475-2875-8-125. PMC 2698916. PMID 19505304.
- ^ Ndiaye JL, Faye B, Gueye A, Tine R, Ndiaye D, Tchania C, et al. (August 2011). "Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial". Malaria Journal. 10: 237. doi: 10.1186/1475-2875-10-237. PMC 3171378. PMID 21838909.
- ^ "DNDi passes the ball to MMV | Medicines for Malaria Venture". www.mmv.org. 22 May 2015. Retrieved 2020-02-13.
External links
- Patient Leaflet
- Monograph (2010) Archived 2021-08-27 at the Wayback Machine
| Combination of | |
|---|---|
| Artesunate | Antimalarial |
| Amodiaquine | Antimalarial |
| Clinical data | |
| Trade names | Camoquin, others [1] |
| Other names | ASAQ |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
|
(what is this?)
(verify) | |
Artesunate/amodiaquine, sold under the trade name Camoquin among others, is a medication used for the treatment of malaria. [3] [4] It is a fixed-dose combination of artesunate and amodiaquine. [3] Specifically it recommended for acute uncomplicated Plasmodium falciparum malaria. [5] It is taken by mouth. [4]
Common side effects include loss of appetite, nausea, abdominal pain, sleepiness, trouble sleeping, and cough. [6] Safety in pregnancy is not clear; however, the medication may be used if others are not possible. [6] It is believed to be safe for use during breastfeeding. [6] Artesunate and amodiaquine are both antimalarial medication; however, work by different mechanisms. [6]
Artesunate/amodiaquine was commercially launched in 2007. [7] It is on the World Health Organization's List of Essential Medicines. [3] Artesunate/amodiaquine is available as a generic medication. [7] As of 2014 it is not commercially available in the United States or United Kingdom. [1] [8]
Medical uses
Early clinical trials showed that a once-a-day dosage was effective. [9] It was subsequently clinically shown to be equally effective as artemether/lumefantrine, [10] although it is likely to be more effective in the field due to its simpler once-a-day dosage compared to artemether/lumefantrine twice-per-day dosage.
Society and culture
Artesunate/amodiaquine was commercially launched in 2007 as an affordable treatment for malaria, devised by DNDi in partnership with Sanofi-Aventis. [7] ASAQ was handed over to the MMV Access and Product Management Team in May 2015. [11]
References
- ^ a b Ainsworth SB (2014). "Amodiaquine with artesunate". Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life. John Wiley & Sons. p. 75. ISBN 9781118819517. Archived from the original on 2016-12-20.
- ^ https://go.drugbank.com/drugs/DB09274
- ^ a b c World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ a b Oyakhirome S, Pötschke M, Schwarz NG, Dörnemann J, Laengin M, Salazar CO, et al. (March 2007). "Artesunate--amodiaquine combination therapy for falciparum malaria in young Gabonese children". Malaria Journal. 6: 29. doi: 10.1186/1475-2875-6-29. PMC 1831475. PMID 17352806.
- ^ World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 187. hdl: 10665/44053. ISBN 9789241547659.
- ^ a b c d "Artesunate Amodiaquine Winthrop" (PDF). WIPO. August 2010. Archived (PDF) from the original on 24 October 2016. Retrieved 12 December 2016.
- ^ a b c "New, Once-a-Day Fixed-Dose Combination Against Malaria Now Available – DNDi". www.dndi.org. 1 March 2007. Archived from the original on 20 December 2016. Retrieved 12 December 2016.
- ^ Rosenthal PJ, Kamya M (2015). "Malaria". In Goldman L, Schafer AI (eds.). Goldman-Cecil Medicine. Elsevier Health Sciences. p. 2112. ISBN 9780323322850. Archived from the original on 2016-12-20.
- ^ Ndiaye JL, Randrianarivelojosia M, Sagara I, Brasseur P, Ndiaye I, Faye B, et al. (June 2009). "Randomized, multicentre assessment of the efficacy and safety of ASAQ--a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria". Malaria Journal. 8: 125. doi: 10.1186/1475-2875-8-125. PMC 2698916. PMID 19505304.
- ^ Ndiaye JL, Faye B, Gueye A, Tine R, Ndiaye D, Tchania C, et al. (August 2011). "Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial". Malaria Journal. 10: 237. doi: 10.1186/1475-2875-10-237. PMC 3171378. PMID 21838909.
- ^ "DNDi passes the ball to MMV | Medicines for Malaria Venture". www.mmv.org. 22 May 2015. Retrieved 2020-02-13.
External links
- Patient Leaflet
- Monograph (2010) Archived 2021-08-27 at the Wayback Machine